Vitafoods Europe 2026: ProBiotix Health to launch instant melt probiotics for menopause

ProBiotix Health plans to debut an instant melt format for its YourBiotix Instant Melt formulation, which addresses long-term cardiovascular and bone health risks during menopause. The gut health solution is based on the company’s clinically validated probiotic strain LPLDL (Lactobacillus plantarum), blended with isoflavones, thiamine, and vitamins D and B6. 

The ingredient showcase at the upcoming Vitafoods Europe 2026 trade fair in Barcelona, Spain (May 5–7), where visitors will be able to taste test the new format that instantly melts on the tongue without any water.

“Many organizations are now seeking solutions that align with future regulatory and safety expectations due to evolving scrutiny around ingredients such as Monacolin K,” says Cellan Davies, head of Marketing.

Alternative to Monacolin K

Monacolin K is a fermented red rice compound identical to prescription lovastatin used for menopausal heart health, which faces a total ban in the EU by late 2026 as regulators tighten safety limits.

To offer an alternative, ProBiotix identified and developed its IP-protected probiotic strain LPLDL using its proprietary ProScreen technology that isolates high-performance probiotic strains from massive candidate pools. The company launched the probiotic at last year’s CPHI trade show in Frankfurt, Germany.

ProBiotix notes that LPLDL can improve key biomarkers related to cardiometabolic health.

“For nutraceutical developers, this is our period of rapid reformulation,” Davies continues. “It is causing the industry to revisit ingredient selection and reconsider other formulation opportunities that perhaps were not possible before. This is driving momentum in scientifically validated alternatives and new approaches to cardiometabolic health.”

Davies stresses that reformulation should not only be a response to regulatory pressures. He sees it as an opportunity to innovate and push for precision probiotics that target wider physiological strategies.

“As a company that develops precision probiotic solutions, we understand that reformulation comes with its own subset of challenges outside of ingredient selection. You must balance multiple priorities, not just from a regulatory perspective, but also consider how your product can differentiate itself from others already in the market, alongside rebuilding consumer confidence by demonstrating clinical efficacy.”

Probiotics for menopause

YourBiotixMH is designed specifically for women during or after menopause, explains Davies. “Research has highlighted that postmenopausal women are five times more likely to suffer from a heart attack, while 77% of women aged over 45 and over have raised cholesterol,” he details.

“This is due to declining estrogen levels, which can further impact heart health, bone density, and mood. There is also substantial evidence that many symptomatic women suffer in silence through hot flashes and night sweats, often unaware that their declining estrogen levels put them more at risk for other health conditions.”

Independent human intervention studies carried out by the UK institutions University of Reading and University of Roehampton support the solution’s benefits for cardiometabolic health.

Their results suggest that LPLDL significantly reduced total cholesterol by up to 37%, low-density lipoprotein (“bad” cholesterol) by 36%, while lowering apolipoprotein B (the main structural protein found on all potentially artery-clogging cholesterol particles) by 28%, and blood pressure by 5%.

Beyond symptomatic relief

A recent study from Mayo Clinic found that menopausal women tend to navigate this life stage without seeking the proper care to help ease their symptoms. The survey of nearly 5,000 women aged 45–60 found that more than three out of four respondents experienced menopause symptoms.

However, Davies underscores a “growing unmet need” for solutions targeting more than just symptomatic relief. Estrogen plays such a protective role in maintaining healthy cholesterol levels, vascular function, and arterial health.

“Recent advances in cardiometabolic science mean we’re now moving away from single-pathway cholesterol inhibitors toward multi-pathway metabolic support,” he highlights.

“From a product viewpoint, we’re reviewing combinations of ingredients that are purposefully designed to influence lipid metabolism, blood pressure regulation, and systemic metabolic balance. Precision probiotics that target microbiome modulation are uniquely positioned to address these needs for healthier cholesterol maintenance.”

In other nutraceutical research centered on menopause, a clinical study from Maastricht University in the Netherlands recently demonstrated the skin health benefits of Bonolive, Solabia Nutrition’s ingestible Manzanilla olive leaf extract. Previous research backed the ingredient’s benefits for menopausal women’s healthy bones, joints, and blood lipid levels.